Narrative
Research conducted at the University of Manchester (UoM) has brought about significantly improved management of neurofibromatosis type 2 (NF2) and neurofibromatosis type 1 (NF1). The demonstration of a survival advantage in NF2 from specialist management centres by Evans and the pioneering work on brain stem/cochlear implants by Ramsden and team were deciding factors for the creation of nationally commissioned services for NF1 and NF2 in 2009 and 2010. All 850 patients with NF2 in England and ~800 complex NF1 patients are now managed through the national services. This specialist management of neurofibromatoses leads to improved life expectancy.| Impact date | 2009 |
|---|---|
| Category of impact | Health impacts, Economic impacts, Societal impacts |
| Impact level | Benefit |
Documents & Links
Related content
-
Research output
-
Predictors of the risk of mortality in neurofibromatosis 2
Research output: Contribution to journal › Article › peer-review
-
Guidelines for the diagnosis and management of individuals with neurofibromatosis
Research output: Contribution to journal › Article › peer-review
-
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): Evidence for more severe disease associated with truncating mutations
Research output: Contribution to journal › Article › peer-review
-
Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis
Research output: Contribution to journal › Article › peer-review